<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Financings</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Financings for June 5, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Artan, Celcuity, Cerevasc, Imunon, Jade, Olix, Parabilis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731639</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731639-financings-for-june-5-2026</link>
    </item>
    <item>
      <title>Hemab soars 89% on debut as biopharma IPOs stay strong in May</title>
      <description>
        <![CDATA[Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731635</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731635-hemab-soars-89-on-debut-as-biopharma-ipos-stay-strong-in-may</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gray-and-green-glass-dollar-symbols-with-arrow-pointing-up.webp?t=1731016850" type="image/jpeg" medium="image" fileSize="116588">
        <media:title type="plain">Gray and green glass dollar symbols with arrow pointing up</media:title>
      </media:content>
    </item>
    <item>
      <title>Seed funding at Artan Bio supports work on aging</title>
      <description>
        <![CDATA[Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731677</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731677-seed-funding-at-artan-bio-supports-work-on-aging</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Aging-and-molecules-concept-art.webp?t=1749159445" type="image/jpeg" medium="image" fileSize="936470">
        <media:title type="plain">Woman and molecular overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for June 4, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Advanced Nanotherapies, Bluejay, Liminatus, Lixte, Medtronic, Mineralys, Nrx.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731625</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731625-financings-for-june-4-2026</link>
    </item>
    <item>
      <title>Ona raises $86.6M series B for ADCs to treat advanced cancers</title>
      <description>
        <![CDATA[Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731620</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731620-ona-raises-866m-series-b-for-adcs-to-treat-advanced-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Idefine announces Kleefstra syndrome gene therapy collaboration</title>
      <description>
        <![CDATA[Idefine, The Kleefstra Syndrome Foundation, has established a collaboration with UT Southwestern Medical Center to advance development of a potential gene therapy to treat Kleefstra syndrome, a rare neurodevelopmental disorder caused by changes or loss of the <em>EHMT1</em> gene, which plays a critical role in brain development and function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731656</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731656-idefine-announces-kleefstra-syndrome-gene-therapy-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-therapy-research-pic.webp?t=1588872515" type="image/png" medium="image" fileSize="467422">
        <media:title type="plain">DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CEPI backs Pop Biotechnologies’ nanoparticle vaccine platform</title>
      <description>
        <![CDATA[The Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $9.7 million in additional funding to Pop Biotechnologies Inc. to advance the company’s Pop Bio SNAP (Spontaneous Nanoliposome Antigen Particle) protein vaccine platform into a phase I trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731654</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731654-cepi-backs-pop-biotechnologies-nanoparticle-vaccine-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Nanoparticle-illustration.webp?t=1735833924" type="image/jpeg" medium="image" fileSize="311893">
        <media:title type="plain">Nanoparticle illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for June 3, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Newlimit, Tavo, Teleflex, Waypoint.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731548</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731548-financings-for-june-3-2026</link>
    </item>
    <item>
      <title>Mammogen raises $30M for blood-based breast cancer detection assay</title>
      <description>
        <![CDATA[Mammogen Inc. raised $30 million in equity financing in a series A round to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform. The company’s lead product is Gentru-breast, a blood-based assay designed to detect molecular signatures associated with breast cancer from a simple blood draw. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731541</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731541-mammogen-raises-30m-for-blood-based-breast-cancer-detection-assay</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>IMU’s $53M series A to advance high-definition immune profiling tech</title>
      <description>
        <![CDATA[IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731669</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731669-imus-53m-series-a-to-advance-high-definition-immune-profiling-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pound-sign-on-tech-background.webp?t=1780434872" type="image/jpeg" medium="image" fileSize="224337">
        <media:title type="plain">Pound sign on tech background</media:title>
      </media:content>
    </item>
    <item>
      <title>Tavo Biotherapeutics closes series A to advance ocular pipeline</title>
      <description>
        <![CDATA[Tavo Biotherapeutics Inc. has successfully closed a $17 million series A financing, with the proceeds directed to advancing the company’s pipeline of innovative therapies targeting glaucoma and retinal disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731597</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731597-tavo-biotherapeutics-closes-series-a-to-advance-ocular-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-dollar-money-eye.webp?t=1768232936" type="image/jpeg" medium="image" fileSize="763744">
        <media:title type="plain">Close-up of a human eye featuring a dollar sign in the iris</media:title>
      </media:content>
    </item>
    <item>
      <title>MJFF awards grant to Montara Therapeutics’ mTOR program</title>
      <description>
        <![CDATA[Montara Therapeutics Inc. has been awarded a research grant of approximately $1 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance a Brainonly therapy targeting mTOR for Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731595</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731595-mjff-awards-grant-to-montara-therapeutics-mtor-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinsons-neurons-Lewy-bodies.webp?t=1642020118" type="image/png" medium="image" fileSize="441475">
        <media:title type="plain">Parkinson's disease illustration showing neurons containing alpha-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Longbio to raise HK$1.4B in Hong Kong IPO for immunology work</title>
      <description>
        <![CDATA[Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731646</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731646-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-illustration.webp?t=1665175609" type="image/png" medium="image" fileSize="332663">
        <media:title type="plain">HKEX on phone, digital stock chart</media:title>
        <media:description type="plain">Credit: piter2121 - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Financings for June 2, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Briacell, Oak Hill, Yoltech.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731534</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731534-financings-for-june-2-2026</link>
    </item>
    <item>
      <title>IMU’s $53M series A to advance high-definition immune profiling tech</title>
      <description>
        <![CDATA[IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731528</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731528-imus-53m-series-a-to-advance-high-definition-immune-profiling-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pound-sign-on-tech-background.webp?t=1780434872" type="image/jpeg" medium="image" fileSize="224337">
        <media:title type="plain">Pound sign on tech background</media:title>
      </media:content>
    </item>
    <item>
      <title>MJFF grants supports Lysoway’s TMEM175 agonist program</title>
      <description>
        <![CDATA[Lysoway Therapeutics Inc. has been awarded an additional research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of its TMEM175 agonist program for Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731583</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731583-mjff-grants-supports-lysoways-tmem175-agonist-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Series A financing at Waypoint Bio supports CAR T programs</title>
      <description>
        <![CDATA[Waypoint Bio has closed a $20 million series A financing round to support its work developing next-generation in vivo CAR T therapeutics for solid tumors using a platform that integrates AI, computer vision and spatial pooled screening.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731579</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731579-series-a-financing-at-waypoint-bio-supports-car-t-programs</link>
    </item>
    <item>
      <title>Financings for June 2, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Hanchorbio, Longbio.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731612</guid>
      <pubDate>Tue, 02 Jun 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731612-financings-for-june-2-2026</link>
    </item>
    <item>
      <title>Financings for June 1, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Longbio, OSE, Outlook, Tempest.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731520</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731520-financings-for-june-1-2026</link>
    </item>
    <item>
      <title>Laverock Therapeutics awarded innovation grants</title>
      <description>
        <![CDATA[Laverock Therapeutics Ltd. has been awarded two new grants totaling in excess of £2.2 million (US$3 million) to support the next generation of its gene-control platform development, and expansion into additional nononcology therapeutics areas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731559</guid>
      <pubDate>Mon, 01 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731559-laverock-therapeutics-awarded-innovation-grants</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for May 29, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Countable Labs, Maculaser, Medicenna, Medicus, Polaryx, Psilera, Secretome, Veraxa.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731462</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731462-financings-for-may-29-2026</link>
    </item>
    <item>
      <title>Longbio to raise HK$1.4B in Hong Kong IPO for immunology work</title>
      <description>
        <![CDATA[Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731445</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731445-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-illustration.webp?t=1665175609" type="image/png" medium="image" fileSize="332663">
        <media:title type="plain">HKEX on phone, digital stock chart</media:title>
        <media:description type="plain">Credit: piter2121 - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Financings for May 28, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Assembly, Bleednfire, Clearnote Health, Kardigan, Protuoso, Q32, Reprogram.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731448</guid>
      <pubDate>Thu, 28 May 2026 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731448-financings-for-may-28-2026</link>
    </item>
    <item>
      <title>Protuoso Biosciences building multifunctional protein engineering platform</title>
      <description>
        <![CDATA[Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731477</guid>
      <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731477-protuoso-biosciences-building-multifunctional-protein-engineering-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-drug-development.webp?t=1663858388" type="image/png" medium="image" fileSize="1141393">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>Reprogram Biosciences secures financing for solid tumor mRNA work</title>
      <description>
        <![CDATA[Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731476</guid>
      <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731476-reprogram-biosciences-secures-financing-for-solid-tumor-mrna-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/AI-digital-dollar-coins.webp?t=1588782231" type="image/png" medium="image" fileSize="299797">
        <media:title type="plain">Wireframe hands, coins</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for May 27, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Biostem, Cartesian, Editas, Hanchorbio, Kane, Mindmaze, Nanobiotix, Rani.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731427</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731427-financings-for-may-27-2026</link>
    </item>
    <item>
      <title>Financings for May 26, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Assembly, HCW, Jupiter, Nanobiotix, Nervgen, Synakis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731413</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731413-financings-for-may-26-2026</link>
    </item>
    <item>
      <title>Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline </title>
      <description>
        <![CDATA[Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat <em>H. pylori</em> infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731470</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731470-tennors-80m-hong-kong-ipo-to-fund-antibacterial-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibiotics-petri-dish.webp?t=1588349786" type="image/png" medium="image" fileSize="499611">
        <media:title type="plain">Petri dish and capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for May 26, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Accro, Forlong, Full-Life Technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731433</guid>
      <pubDate>Tue, 26 May 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731433-financings-for-may-26-2026</link>
    </item>
    <item>
      <title>Financings for May 22, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Aim Immunotech, Akari, Immix, Jupiter, Relay, Theralase.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731395</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731395-financings-for-may-22-2026</link>
    </item>
  </channel>
</rss>
